Pentixapharm AG Alternatives & Competitors
12 companies similar to Pentixapharm AG — improves the life of patients with malignant diseases through targeted molecular...
Companies similar to Pentixapharm AG
RayzeBio
Targeted innovative radiopharmaceuticals for cancer
San Diego, United States
Viewpoint Molecular Targeting, Inc.
Targeted α-Particle Radiotherapy for Cancer
Coralville, United States
CatalYm GmbH
Developing innovative immunotherapies to transform cancer patients’ lives by engaging thei...
Germany
Avenzo Therapeutics
Developing the next generation of oncology therapies for patients
San Diego, United States
Track all Pentixapharm AG competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
BeyondSpring
Based in Duncan, South Carolina, we are a pioneering biotechnology company dedicated to ad...
New York, United States
OXFORD VACMEDIX UK LIMITED
Developing therapeutic cancer vaccines using ROP technology
Oxford, United Kingdom
Kestrel Therapeutics
We aspire to invent brilliant technologies for difficult cancer targets, beginning with mu...
Watertown, United States
Orum Therapeutics
A public biotechnology company pioneering a novel class of protein degraders.
Lexington, United States
ImaginAb
Be the lead diagnostic and treatment choice...helping patients live better and healthier l...
Inglewood, United States
Blueprint Medicines
Striving to improve and extend patients' lives
Cambridge, United States
Ablaze Pharmaceuticals
Leading the Innovative Targeted Radiotherapy Landscape in China.
Shanghai, China
Breakpoint Therapeutics
Modulating DNA damage responses to cure cancer
Hamburg, Germany
About Pentixapharm AG
Pentixapharm AG is a biotechnology company founded in 2019 and headquartered in Germany. The company is committed to enhancing the lives of patients with malignant diseases by delivering targeted molecular diagnostics and therapies, encapsulated in its slogan: "improves the life of patients with malignant diseases thro...
Development of first-in-class radiopharmaceutical compounds, Phase-III clinical trial management, Advanced PET-Diagnostics for medical conditions
Medical Institutions, Healthcare Professionals, Patients with Hemato-Oncological Conditions
Theranostic Radiopharmaceuticals, Molecular Diagnostics, Oncology, Radiopharmaceutical Development, CXCR4-receptor Targeting, CNS Lymphoma, Phase II Trials, Phase I Trials, Cancer Therapy, Targeted Therapy, Radiopharmaceutical Pair, Proof-of-Concept Studies
B2B, B2B2C
Product Sales, Licensing
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Pentixapharm AG and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Pentixapharm AG on 14 May 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
